Technical Trend Shift and Price Movement
Concord Biotech’s current price stands at ₹1,186.05, down 2.91% from the previous close of ₹1,221.55. The stock’s intraday range on 4 Mar 2026 was between ₹1,166.40 and ₹1,224.95, reflecting heightened volatility. Over the past 52 weeks, the share has traded between a low of ₹1,056.75 and a high of ₹2,149.90, indicating a significant retracement from its peak.
The technical trend has shifted from mildly bearish to outright bearish, signalling increased downside pressure. This shift is corroborated by multiple technical indicators across different timeframes.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly chart, suggesting that the stock’s momentum is weakening. Although the monthly MACD does not currently provide a clear signal, the weekly bearish stance indicates that short- to medium-term momentum is negative. This is a critical warning sign for investors relying on momentum-based strategies.
The Know Sure Thing (KST) indicator also aligns with this bearish outlook on the weekly timeframe, reinforcing the momentum deterioration. The absence of a clear monthly KST signal suggests that longer-term momentum remains uncertain but is not yet positive.
Relative Strength Index and Bollinger Bands
The Relative Strength Index (RSI) on both weekly and monthly charts shows no definitive signal, hovering in neutral territory. This indicates that the stock is neither overbought nor oversold, but the lack of upward momentum is concerning given the broader bearish context.
Bollinger Bands on both weekly and monthly charts are bearish, signalling that price volatility is skewed towards the downside. The stock price is currently trading near the lower band on the weekly chart, which often suggests increased selling pressure and potential continuation of the downtrend.
Moving Averages and Volume Analysis
Daily moving averages are firmly bearish, with the stock trading below its key short- and medium-term averages. This technical setup typically indicates that sellers are in control and that any rallies may face resistance near these averages.
On-Balance Volume (OBV) analysis shows no clear trend on weekly or monthly charts, suggesting that volume is not confirming any strong directional move. This lack of volume support for price movements adds to the cautionary stance on the stock.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Comparative Performance and Market Context
Despite the recent technical weakness, Concord Biotech has outperformed the Sensex over shorter timeframes. The stock posted a 7.91% return over the past week compared to the Sensex’s decline of 3.67%. Similarly, over the last month, Concord Biotech gained 7.13% while the Sensex fell by 1.75%. However, year-to-date and longer-term returns tell a more challenging story, with the stock down 11.85% YTD and 20.59% over the past year, while the Sensex gained 9.62% in the same period.
This divergence highlights the stock’s volatility and the mixed sentiment among investors. The pharmaceutical and biotechnology sector, in which Concord Biotech operates, has faced headwinds from regulatory uncertainties and pricing pressures, which may be contributing to the stock’s technical deterioration.
Dow Theory and Trend Confirmation
According to Dow Theory, there is no clear trend on either the weekly or monthly charts for Concord Biotech. This absence of trend confirmation adds to the uncertainty, suggesting that the stock may be in a consolidation phase or preparing for further directional movement. Investors should be cautious and watch for a decisive breakout or breakdown to confirm the next major trend.
Mojo Score and Grade Update
MarketsMOJO has downgraded Concord Biotech’s Mojo Grade to Sell from Strong Sell as of 26 Feb 2026, reflecting a slight improvement but still signalling caution. The Mojo Score stands at 34.0, indicating weak fundamentals and technicals relative to peers. The Market Cap Grade is 3, suggesting a mid-tier market capitalisation within its sector.
This rating adjustment reflects the mixed signals from technical indicators and the company’s recent price action. While short-term momentum has shown some resilience, the overall technical landscape remains bearish.
Holding Concord Biotech Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway and Outlook
Concord Biotech’s technical indicators collectively point to a bearish momentum shift, with key signals such as the MACD, Bollinger Bands, and moving averages confirming increased selling pressure. The lack of volume confirmation and neutral RSI readings suggest that the stock may continue to face resistance in the near term.
Investors should weigh the recent short-term outperformance against the broader technical deterioration and sector challenges. The stock’s significant retracement from its 52-week high and its underperformance relative to the Sensex over the past year highlight the risks involved.
For those considering entry or exit points, it is prudent to monitor for a clear trend reversal or confirmation of further downside before making significant portfolio adjustments. The absence of a confirmed Dow Theory trend means that technical signals should be interpreted with caution and in conjunction with fundamental analysis.
In summary, Concord Biotech currently exhibits a bearish technical profile with limited upside momentum, warranting a cautious stance for investors and traders alike.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
